Can you provide the last earnings date for NEUROBO PHARMACEUTICALS INC?
NEUROBO PHARMACEUTICALS INC (NRBO) last reported earnings on 11/7/2024.
NASDAQ:NRBO • US64132R4048
Past quarterly earnings results for NEUROBO PHARMACEUTICALS INC (NRBO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2024 | -0.55 | -0.74 | 26.13% | 23.61% | - | - | ||
| Q2 2024 | -1.85 | -1.15 | -61.46% | -1,056.25% | - | - | ||
| Q1 2024 | -1.32 | -3.70 | 64.34% | -72.20% | - | - | ||
| Q4 2023 | -2.28 | -0.80 | -184.75% | 84.34% | - | - | ||
| Q3 2023 | -0.72 | -0.87 | 17.54% | -315.22% | - | - | ||
| Q2 2023 | -0.16 | -1.03 | 84.44% | 7.73% | - | - | ||
| Q1 2023 | -0.77 | -5.14 | 85.09% | -369.71% | - | - | ||
| Q4 2022 | -14.56 | -9.79 | -48.69% | -9,416.34% | - | - | ||
| Q3 2022 | -0.17 | - | 96.39% | - | - | |||
| Q2 2022 | -0.17 | - | 96.79% | - | - | |||
| Q1 2022 | -0.16 | - | 96.37% | - | - | |||
| Q4 2021 | -0.15 | - | 99.58% | - | - | |||
| Q3 2021 | -4.80 | -5.51 | 12.85% | 15.79% | - | - | ||
| Q2 2021 | -5.40 | -4.59 | -17.65% | -20.00% | - | - | ||
| Q1 2021 | -4.50 | -4.90 | 8.09% | 50.00% | - | - | ||
| Q4 2020 | -36.00 | -5.81 | -519.20% | - | - | - | ||
| Q3 2020 | -5.70 | -5.20 | -9.57% | - | - | - | ||
| Q2 2020 | -4.50 | -5.81 | 22.60% | - | - | - | ||
| Q1 2020 | -9.00 | -3.06 | -194.12% | - | - | - |
Notes
NEUROBO PHARMACEUTICALS INC (NRBO) last reported earnings on 11/7/2024.
NEUROBO PHARMACEUTICALS INC (NRBO) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, NEUROBO PHARMACEUTICALS INC (NRBO) has beaten EPS estimates in 2 out of 4 releases.